Full TitlePhase 2 study of Axitinib + PD-1 blockade in Mucosal Melanoma with Pilot Addition of Stereotactic Body Radiotherapy or Ipilimumab in Select Progressors
The purpose of this study is to assess the safety and effectiveness of treatment with axitinib and nivolumab immunotherapy for people with advanced mucosal melanoma that has not yet been treated. Axitinib blocks the development of blood vessels that cancer cells need to grow and spread (“angiogenesis”). Nivolumab boosts the ability of the immune system to detect and destroy cancer cells.
Participants in this study who do not respond well to these two drugs may be offered one of two additional treatments:
- Axitinib and nivolumab plus ipilimumab, another immunotherapy drug, OR
- Axitinib and nivolumab plus stereotactic body radiotherapy (SBRT), which delivers a highly precise beam of radiation to a limited area and spares healthy tissue around the tumor.
Axitinib is taken orally (by mouth) and nivolumab and ipilimumab are given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have metastatic mucosal melanoma that has not yet been treated.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Alexander Shoushtari at 646-888-4161.